Welcome to mysite


Последние (по состоянию на апрель 2012) зарегистированные на рынке орфанные препараты
Раздел: 1)Горячие новости Дата:  10.5.12

Справка портала: Последние (по состоянию на апрель 2012) зарегистированные на рынке орфанные препараты  

Eurodis

(По данным http://www.eurordis.org)

Find out the latest orphan drug designations and market authorisations

March 2012

Treatment of mucopolysaccharidosis type VII (Sly syndrome)
Recombinant human beta-glucuronidase Treatment of primary hyperoxaluria type 1 br />Adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate aminotransferase gene

Treatment of Prader-Willi syndrome
Carbetocin


April 2012



Treatment of 5q spinal muscular atrophy
Antisense oligonucleotide targeted to the SMN2 gene

Treatment of adrenal cortical carcinoma
Linsitinib

Treatment of perinatal asphyxia
Melatonin

Treatment of calciphylaxis
Sodium thiosulfate

Treatment of mucopolysaccharidosis type III (Sanfilippo syndrome)
Genistein sodium salt dihydrate
Treatment of Leber’s congenital amaurosis
Adenovirus associated viral vector serotype 2 containing the human RPE65 gene

Treatment of respiratory distress syndrome in premature neonates of less than 37 weeks of gestational age
Dipalmitoylphosphatidylcholine, 1-palmitoyl-2-oleoyl-snglycero-3-phosphoglycerol, sodium salt, synthetic surfactant protein C analogue and synthetic surfactant protein B analogue

Detailed information on European orphan drug designation applications is available on the EMA website

A full list of designated and authorised orphan drugs in Europe available at: ec.europa.eu

Источник: http://www.eurordis.org






Новость опубликована на сайте Информационный портал по редким заболеваниям.
http://www.rarediseases.ru

Адрес новости:
http://www.rarediseases.ru/article.php?storyid=610